Belite Bio, Inc
BLTE
株式のランク
#3050
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
株価
$148.24
最終同期: 2026-10-19
時価総額
$5.97B
変化（1日）
3.82%
変化（1年）
64.04%
国
US
取引 Belite Bio, Inc (BLTE)
カテゴリー
Healthcare
Belite Bio, Inc（BLTE）の発行済株式数
June 2026 時点の発行済株式数 40.18M
Belite Bio, Inc の最新の財務報告および株価によると、現在の発行済株式数は 40.18M です。December 2023 の終わりには、同社は 26.59M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Belite Bio, Inc（BLTE）の発行済株式数の履歴（2020 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 40.18M | 31.58% |
| 2024 | 30.54M | 14.84% |
| 2023 | 26.59M | 33.12% |
| 2022 | 19.98M | -17.09% |
| 2021 | 24.10M | 161.73% |
| 2020 | 9.21M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 531.87% |
US
|
|
| 396.00M | 885.51% |
US
|
|
| 478.91M | 1,091.85% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 54.76% |
NL
|
